Innocoll AG to Present at JMP Securities Healthcare Conference

ATHLONE, Ireland, June 17, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq: INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that Tony Zook, Chief Executive Officer of Innocoll, will present at the JMP Securities Healthcare Conference at 12:30 p.m. EDT, Wednesday, June 24, at The St. Regis New York in New York City.

A live audio webcast and archive of the presentation will be available on the company website at www.innocoll.com.

About Innocoll AG

Innocoll is a global, commercial-stage, specialty pharmaceutical company. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. The company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColl® for the treatment of post-operative pain; Cogenzia® for the adjuvant treatment of diabetic foot infections; and CollaGUARD®, a barrier for the prevention of post-surgical adhesions. The Company's approved products include: CollaGUARD(Ex-US), Collatamp® G, Septocoll®, RegenePro®, Collieva®, CollaCare®, Collexa®, and Zorpreva™, which are sold through strategic partnerships with various partners including Takeda, Biomet, and EUSA Pharma. All of the company's products and product candidates are made using Type 1 collagen and are manufactured in-house at its facility in Saal, Germany. CollaRx®, Collatamp®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Cogenzia® LidoColl®, LiquiColl®, Septocoll®, and XaraColl® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the company.

CONTACT: Corporate:
         Denise Carter
         Executive Vice President Business Development
         and Corporate Affairs
         (215) 765-0149
         [email protected]

         Investor Contact:
         Russo Partners, LLC
         Robert E. Flamm, Ph.D.
         (212) 845-4226
         [email protected]

You May Also Be Interested In

• Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
• The On-Chain AI Skill Economy · The Standard Layer
• PolicyPantry Launches National Database for U.S. Allergy, Asthma and Anaphylaxis Laws